Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04479852 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
A Phase 2 study, sponsored by Sirtsei Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 319
- Enrollment target
NCT04479852: Completed Phase 2 study, sponsored by Sirtsei Pharmaceuticals.
NCT04479852 is a Phase 2 study that has completed, run by Sirtsei Pharmaceuticals. The registered enrollment target is 319 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (140% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04479852, a Phase 2 study, has completed, sponsored by Sirtsei Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 319 participants
- Enrollment target
Study Summary
This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Primary Outcome
The Montgomery Asberg Depression rating scale is a 10-item scale used to assess the severity of depression. Individual items are scored on a 7-point scale (0 to 6). The total score is the sum of individual items, ranging from 0 to 60; where a higher score indicates more depression.
Interventions
- DRUG Placebo
- DRUG SP-624
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2022-08-09 |
| Phase | Phase 2 |
What the finished NCT04479852 record still lists
NCT04479852 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (140% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04479852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04479852 about?
NCT04479852 is a clinical study titled "A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder". This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
What is the current status of trial NCT04479852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 319 participants. The study started on 2020-09-30. Estimated completion is 2022-08-09.
What interventions are being tested in trial NCT04479852?
The interventions under investigation include: Placebo (DRUG), SP-624 (DRUG).
Who is sponsoring clinical trial NCT04479852?
This trial is sponsored by Sirtsei Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04479852's enrollment target sits among peer trials
319 153rd of 2000 higher than 1,848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05377996 · 319 participants · Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI